Pharmacogenomics of platinum-based chemotherapy in NSCLC.
Pharmacogenomics of platinum-based chemotherapy in NSCLC.
复制标题
NSCLC中基于铂的化学疗法的药物基因组学。
DOI:
10.1517/17425250902973711
复制
发表时间:
2009-07
影响因子:
4.3
通讯作者:
Wu X
中科院分区:
文献类型:
--
作者:
Hildebrandt MA;Gu J;Wu X
NSCLC is the leading cause of cancer-related death in the US. Patients with NSCLC are mostly treated with platinum-based chemotherapy, often in combination with radiation therapy. However, the development of chemoresistance is a major hurdle limiting treatment success. In this review, we summarize the current understanding of the genetic factors modulating chemoresistance to platinum chemotherapeutics and their association with clinical outcomes for NSCLC patients. We focus on candidate pathways responsible for drug influx and efflux, metabolism and detoxification, DNA damage repair, and other downstream cellular processes that modulate the effect of platinum-based therapy. We also discuss the application of pathway-based polygenic and genome-wide approaches in identifying genetic factors involved in NSCLC clinical outcomes. Overall, current studies have shown that the effects of each individual polymorphism on clinical outcomes are modest suggesting that a more comprehensive approach that incorporates polygenetic, phenotypic, epidemiologic and clinical variables will be necessary to predict prognosis for NSCLC patients receiving platinum-based chemotherapeutics.
登录
查看更多内容
影响因子:
30.8
作者:
Dumont, P;Leu, JIJ;Murphy, M
通讯作者:
Murphy, M
DOI:
10.1158/1940-6207.capr-08-0082
发表时间:
2008-09
期刊:
Cancer prevention research (Philadelphia, Pa.)
影响因子:
--
作者:
Etzel CJ;Kachroo S;Liu M;D'Amelio A;Dong Q;Cote ML;Wenzlaff AS;Hong WK;Greisinger AJ;Schwartz AG;Spitz MR
通讯作者:
Spitz MR
影响因子:
5.3
作者:
Bepler, G;Zheng, Z;Haura, E
通讯作者:
Haura, E
影响因子:
4.7
作者:
Chen, Meng;Kamat, Ashish M.;Gu, Jian
通讯作者:
Gu, Jian
DOI:
10.1073/pnas.0601231103
发表时间:
2006-04-11
影响因子:
11.1
作者:
Ein-Dor, L;Zuk, O;Domany, E
通讯作者:
Domany, E